Skip to main
VYGR
VYGR logo

Voyager Therapeutics (VYGR) Stock Forecast & Price Target

Voyager Therapeutics (VYGR) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Voyager Therapeutics is positioned for positive revenue growth through its TRACER platform, which is expected to generate income from collaborations advancing to clinical trials in the 2030s. The company has demonstrated substantial efficacy in preclinical studies, showcasing a significant reduction in tau mRNA and protein levels, which suggests that its therapies could provide durable benefits with lower liver exposure compared to traditional methods. Additionally, the innovative NeuroShuttle technology has shown enhanced durability and safety in CNS exposure, further solidifying the potential of Voyager's gene therapy solutions in treating severe neurological diseases.

Bears say

The analysis of Voyager Therapeutics highlights several fundamental concerns that contribute to a negative outlook for the company's stock. Despite its innovative gene therapy platform and focus on severe neurological diseases, the company faces substantial financial challenges, including limited revenue generation and high operational costs associated with research and development. Furthermore, ongoing risks related to the lengthy regulatory approval processes for its therapies and potential setbacks in clinical trials may impede the company's ability to achieve sustainable growth and profitability in the near term.

Voyager Therapeutics (VYGR) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Voyager Therapeutics (VYGR) Forecast

Analysts have given Voyager Therapeutics (VYGR) a Buy based on their latest research and market trends.

According to 5 analysts, Voyager Therapeutics (VYGR) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Voyager Therapeutics (VYGR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.